Trial Profile
A Single Dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic Rhinitis Subjects Challenged Intranasally With Allergen Extract
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs REGN 1908-1909 (Primary)
- Indications Hypersensitivity
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 02 Mar 2021 Results published in the American Journal of Respiratory and Critical Care Medicine
- 11 Jan 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 12 Jun 2015 Planned End Date changed from 1 Aug 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.